174 filings
8-K
ME
23andMe Holding Co - Ordinary Shares
18 Apr 24
23andMe announces CEO’s intention to pursue a potential take-private
8:07am
8-K
ME
23andMe Holding Co - Ordinary Shares
29 Mar 24
Departure of Directors or Certain Officers
12:46pm
S-8
ME
23andMe Holding Co - Ordinary Shares
22 Mar 24
Registration of securities for employees
5:02pm
8-K
ME
23andMe Holding Co - Ordinary Shares
7 Feb 24
23andMe Reports Third Quarter Fiscal 2024 Financial Results
4:03pm
8-K
ck7 pge9zoejtb
31 Jan 24
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
7:50am
8-K
ta58lno6
8 Jan 24
Regulation FD Disclosure
7:45am
8-K/A
lhvyx4ui1
1 Dec 23
Regulation FD Disclosure
4:06pm
8-K
kzkknrc160s0a715v
13 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
s0c0yfnv78wktz7k2n
8 Nov 23
23andMe Reports Second Quarter Fiscal 2024 Financial Results
4:29pm
8-K
42hbq9p im1
6 Nov 23
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
8:15am
8-K
jeydbafetr
30 Oct 23
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
4:05pm
8-K
qsqc 1a2w40glvgfk
27 Oct 23
Departure of Directors or Certain Officers
4:06pm
8-K
mjv7nufwkbit3xdg4ad
10 Oct 23
Regulation FD Disclosure
4:17pm
8-K
8p4ttldb hixbpkj6y
19 Sep 23
Departure of Directors or Certain Officers
4:06pm
S-8
s0c4of491kwga
15 Sep 23
Registration of securities for employees
4:06pm
8-K
be30fz9t8
11 Sep 23
Departure of Directors or Certain Officers
4:06pm
8-K
wzn6vn d9sg9
1 Sep 23
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
12:00am